Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.22.2.2
Research and Development Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2021
Feb. 28, 2021
Sep. 30, 2018
Sep. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Research And Development Collaboration Agreements [Line Items]                  
Research and development revenue recognized       $ 4,240,000     $ 2,379,000 $ 17,143,000 $ 20,733,000
Revenue from grant       4,240,000     $ 2,379,000 17,143,000 20,733,000
Grant                  
Research And Development Collaboration Agreements [Line Items]                  
Revenue from grant               0 $ 0
CPRIT Agreement | Cancer Prevention and Research Institute of Texas                  
Research And Development Collaboration Agreements [Line Items]                  
Product development grant awarded     $ 15,200,000            
Grant Agreements | Grants Revenue Receivable                  
Research And Development Collaboration Agreements [Line Items]                  
Reimbursement amounts submitted in excess of amounts received are recorded as receivables       0   $ 0   0  
Bristol Myers Squibb Collaboration Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Upfront payment   $ 70,000,000.0              
Milestone payments receivable if option is exercised   874,500,000              
Transaction price allocated to performance obligations   70,000,000.0              
Deferred revenue, current       38,100,000   32,800,000   38,100,000  
Deferred revenue, non-current       14,600,000   30,700,000   14,600,000  
Bristol Myers Squibb Collaboration Agreement | Sales Milestone                  
Research And Development Collaboration Agreements [Line Items]                  
Milestone payments receivable if option is exercised   $ 450,000,000.0              
Vertex Collaboration Agreement                  
Research And Development Collaboration Agreements [Line Items]                  
Research and development revenue recognized           14,600,000      
Takeda Development Agreement | Maximum                  
Research And Development Collaboration Agreements [Line Items]                  
Clinical and regulatory milestone payments $ 22,250,000                
Takeda Multi Target Agreement | Takeda Pharmaceuticals Inc                  
Research And Development Collaboration Agreements [Line Items]                  
Research and development revenue recognized         $ 2,600,000        
Deferred revenue       $ 0   $ 2,600,000   $ 0